Administrative Core
- Institution
- METHODIST HOSPITAL RESEARCH INSTITUTE, TX
- Principal investigator
- Keith Syson Chan
- Funding
- $312K
- Duration
- 2022–2027
Moonbase score
Still being scored
Abstract
ADMINISTRATIVE CORE PROJECT SUMMARY The Leadership Administrative Core (Core A) will provide scientific, administrative, fiscal, and organizational coordination of all the activities of the Projects and Cores to ensure this Program Project Grant (PPG) meets all of the proposed scientific goals. This will be achieved by providing an organized infrastructure to: 1) streamline effective communications internal and external to the Program (e.g., annual reporting and publications), and promote synergistic collaborations among the three Projects, the Resource Sharing Core, and selection of external collaborative projects (i.e., distribution of collaborative funds), 2) perform fiscal management and administration, 3) provide annual and mid-point evaluation to stimulate progress towards accomplishing the overall scientific goals of the U54 Program, 4) ensure research is conducted under the highest ethical and scientific standards. Our Program represents a multidisciplinary team of NCI-funded “organ-specific” bladder cancer investigators within Cedars-Sinai Medical Center to investigate the stromal microenvironment as a co- organizer of bladder carcinogenesis and progression.
LOADING MOONBASE SCORE
Questions for METHODIST HOSPITAL RESEARCH INSTITUTE
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · Methodist Hospital Research InstituteNot yet scored
The stromal microenvironment as a co-organizer of bladder carcinogenesis and progression
Keith Syson Chan · $1.6M · 2022–2027
- NIH · Methodist Hospital Research InstituteNot yet scored
Project 1
Keith Syson Chan · $356K · 2022–2027
- NIH · Methodist Hospital Research InstituteNot yet scored
Targeting tumor repopulation and the immune microenvironment to overcome chemoresistance
Keith Syson Chan · $453K · 2021–2026